Regulation of cancer cell migration and bone metastasis by RANKL.
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Bone metastases are a frequent complication of many cancers that result in severe disease burden and pain. Since the late nineteenth century, it has been thought that the microenvironment of the local host tissue actively participates in the propensity of certain cancers to metastasize to specific organs, and that bone provides an especially fertile 'soil'. In the case of breast cancers, the local chemokine milieu is now emerging as an explanation for why these tumours preferentially metastasize to certain organs. However, as the inhibition of chemokine receptors in vivo only partially blocks metastatic behaviour, other factors must exist that regulate the preferential metastasis of breast cancer cells. Here we show that the cytokine RANKL (receptor activator of NF-kappaB ligand) triggers migration of human epithelial cancer cells and melanoma cells that express the receptor RANK. RANK is expressed on cancer cell lines and breast cancer cells in patients. In a mouse model of melanoma metastasis, in vivo neutralization of RANKL by osteoprotegerin results in complete protection from paralysis and a marked reduction in tumour burden in bones but not in other organs. Our data show that local differentiation factors such as RANKL have an important role in cell migration and the tissue-specific metastatic behaviour of cancer cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MDA-231 cells and other human breast cancer cells have been shown to express RANK (101, 336)”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [336]
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Self-citationInvolvement of chemokine receptors in breast cancer metastasis
Müller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S. N., et al. (2001) · Nature · doi:10.1038/35065016 · Cited by 5,340
The distribution of secondary growths in cancer of the breast.
Paget, S. (1889) · The Lancet · doi:10.1016/s0140-6736(00)49915-0 · Cited by 5,277
Bone Resorption by Osteoclasts
Teitelbaum, S. L. (2000) · Science · doi:10.1126/science.289.5484.1504 · Cited by 3,962
Dissemination and growth of cancer cells in metastatic sites
Chambers, A. F., Groom, A. C., & MacDonald, I. C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc865 · Cited by 3,911
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351
Self-citationMetastasis to bone: causes, consequences and therapeutic opportunities
Mundy, G. R. (2002) · Nature Reviews Cancer · doi:10.1038/nrc867 · Cited by 2,777
The microenvironment of the tumour–host interface
Liotta, L. A., & Kohn, E. C. (2001) · Nature · doi:10.1038/35077241 · Cited by 2,310
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.
Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., & Galibert, L. (1997) · Nature · doi:10.1038/36593 · Cited by 2,290
Fata, J. E., Kong, Y.-Y., Li, J., Sasaki, T., Irie-Sasaki, J., Moorehead, R. A., Elliott, R., Scully, S., Voura, E. B., Lacey, D. L., et al. (2000) · Cell · doi:10.1016/s0092-8674(00)00103-3 · Cited by 756
Self-citation
Cited by
Items 101–200 of 864
The influence of tumour-derived extracellular vesicles on local and distal metastatic dissemination
Nogués, L., Benito-Martin, A., Hergueta-Redondo, M., & Peinado, H. (2018) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.11.012 · Cited by 118
Targeting bone metastases in prostate cancer: improving clinical outcome
Body, J., Casimiro, S., & Costa, L. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2015.90 · Cited by 132
Endocrine aspects of bone metastases
Hofbauer, L. C., Rachner, T. D., Coleman, R. E., & Jakob, F. J. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70203-1 · Cited by 132
The immune system, bone and RANKL
Guerrini, M. M., & Takayanagi, H. (2014) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2014.06.003 · Cited by 129
Denosumab in patients with cancer and skeletal metastases: A systematic review and meta-analysis
Peddi, P., Lopez-Olivo, M. A., Pratt, G. F., & Suarez-Almazor, M. E. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.07.002 · Cited by 128
Breast Cancer Cell Colonization of the Human Bone Marrow Adipose Tissue Niche
Templeton, Z. S., Lie, W.-R., Wang, W., Rosenberg-Hasson, Y., Alluri, R. V., Tamaresis, J. S., Bachmann, M. H., Lee, K., Maloney, W. J., Contag, C. H., et al. (2015) · Neoplasia · doi:10.1016/j.neo.2015.11.005 · Cited by 123
“[10] Jones DH, Nakashima T, Sanchez OH, Kozieradzki I, Komarova SV, Sarosi I,”
BackgroundCancer Cell Colonisation in the Bone Microenvironment
Kan, C. W. S., Vargas, G., Pape, F. L., & Clézardin, P. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17101674 · Cited by 126
“Gene expression analysis showed increased RANKL and DKK-1 and decreased OPG; this was accompanied by increased MMP-9 and cathepsin K activity, suggesting increased bone resorption through elevated osteoclast activity [85].”
BackgroundInfluentialThe Contribution of the Immune System in Bone Metastasis Pathogenesis
Xiang, L., & Gilkes, D. M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040999 · Cited by 126
“In addition, DTCs expressing RANK can interact with RANKL which is secreted by osteoblasts and osteocytes in bone environments [31,32].”
BackgroundCancer metastasis networks and the prediction of progression patterns
Chen, L. L., Blumm, N., Christakis, N. A., Barabási, A.-L., & Deisboeck, T. S. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605214 · Cited by 111
“Studies suggest that this receptor– ligand combination may predispose breast cancer cells to colonise bone (Roodman, 2004; Yoneda and Hiraga, 2005; Jones et al, 2006).”
BackgroundBone-Targeted Therapies in Cancer-Induced Bone Disease
Sousa, S., & Clézardin, P. (2017) · Calcified Tissue International · doi:10.1007/s00223-017-0353-5 · Cited by 125
“RANK is expressed by osteoclasts and osteoclast precursors, whereas RANKL is produced by osteoblasts and osteocytes [52].”
BackgroundSaidak, Z., Boudot, C., Abdoune, R., Petit, L., Brazier, M., Mentaverri, R., & Kamel, S. (2009) · Experimental Cell Research · doi:10.1016/j.yexcr.2009.03.003 · Cited by 125
Alveolar and Lactogenic Differentiation
Brisken, C., & Rajaram, R. D. (2006) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-006-9026-0 · Cited by 123
“However, biochemical evidence demonstrating the induction of Cyclin D1 by RANKL in the mammary epithelium is still missing [41, 45, 46].”
BackgroundSafety Concern between Autologous Fat Graft, Mesenchymal Stem Cell and Osteosarcoma Recurrence
Perrot, P., Rousseau, J., Bouffaut, A.-L., Rédini, F., Cassagnau, E., Deschaseaux, F., Heymann, M.-F., Heymann, D., Duteille, F., Trichet, V., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010999 · Cited by 120
“In another hand, adipocytes highly express Adiponectin (also designed as adipose most abundant gene transcript) which was shown to stimulate Receptor Activator of NF-kB Ligand (RANKL or TNFSF11) and inhibit Osteoprotegerin expression in osteoblasts [29].”
BackgroundDanks, L., & Takayanagi, H. (2013) · The Journal of Biochemistry · doi:10.1093/jb/mvt049 · Cited by 119
Kim, M. Y. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9620-6_9 · Cited by 119
Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas
Mikami, S., Katsube, K., Oya, M., Ishida, M., Kosaka, T., Mizuno, R., Mochizuki, S., Ikeda, T., Mukai, M., & Okada, Y. (2009) · The Journal of Pathology · doi:10.1002/path.2567 · Cited by 118
“RANKL triggers the migration of cancer cells expressing RANK [5,13].”
BackgroundEvolution of cellular morpho-phenotypes in cancer metastasis.
Wu, P.-H., Phillip, J. M., Khatau, S. B., Chen, W.-C., Stirman, J., Rosseel, S., Tschudi, K., Van Patten, J., Wong, M., Gupta, S., et al. (2015) · Scientific Reports · doi:10.1038/srep18437 · Cited by 117
Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
Irie, A., Takami, M., Kubo, H., Sekino-Suzuki, N., Kasahara, K., & Sanai, Y. (2007) · Bone · doi:10.1016/j.bone.2007.04.190 · Cited by 116
“Because OPG neutralizes RANKL activity, it has been thought that OPG might be used to treat osteoporosis, rheumatoid arthritis, and RANKL-mediated bone metastasis [50,51].”
BackgroundTsubaki, M., Komai, M., Fujimoto, S.-I., Itoh, T., Imano, M., Sakamoto, K., Shimaoka, H., Takeda, T., Ogawa, N., Mashimo, K., et al. (2013) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-32-62 · Cited by 110
“RANKL accelerates the migration and metastasis of cancer cells expressing RANK [16-18].”
BackgroundOsteoclast Signal Transduction During Bone Metastasis Formation
Győri, D., & Mócsai, A. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00507 · Cited by 115
“RANK receptor expression by melanoma, breast and prostate cancer cell lines has also been described (Jones et al., 2006), and involved in the autocrine effect of tumor cell-derived RANKL on promoting cancer cell migration.”
BackgroundWu, X., Li, F., Dang, L., Liang, C., Lü, A., & Zhang, G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00076 · Cited by 112
“However, most patients in the advanced stages of the disease lose TGF-β-mediated growth inhibition but still retain TGF-β-mediated regulation of their metastasis-promoting genes (Käkönen et al., 2002; Wakefield and Roberts, 2002).”
BackgroundCrystal Structure of Human RANKL Complexed with Its Decoy Receptor Osteoprotegerin
Luan, X., Lu, Q., Jiang, Y., Zhang, S., Wang, Q., Yuan, H., Zhao, W., Wang, J., & Wang, X. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103387 · Cited by 112
BACH1, the master regulator gene: A novel candidate target for cancer therapy
Davudian, S., Mansoori, B., Shajari, N., Mohammadi, A., & Baradaran, B. (2016) · Gene · doi:10.1016/j.gene.2016.04.040 · Cited by 110
“Also, a recent study depicted the role of the receptor activator of nuclear factor-κB (RANK)/RANK ligand in metastasis of breast cancer cells to bone (Jones et al., 2006).”
BackgroundEfficacy of an orally active small-molecule inhibitor of RANKL in bone metastasis
Nakai, Y., Okamoto, K., Terashima, A., Ehata, S., Nishida, J., Imamura, T., Ono, T., & Takayanagi, H. (2019) · Bone Research · doi:10.1038/s41413-018-0036-5 · Cited by 110
Yue, Z., Niu, X., Yuan, Z., Qin, Q., Jiang, W., He, L., Gao, J., Ding, Y., Liu, Y., Xu, Z., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci144579 · Cited by 110
“RANKL secreted by BCa cells promotes their own growth and eventual metastasis to the bone, where BCa-secreted RANKL also induces osteoclast activation and bone resorption, driving the vicious cycle described above (12, 13).”
BackgroundDittmar, T., Heyder, C., Gloria-Maercker, E., Hatzmann, W., & Zänker, K. S. (2007) · Clinical & Experimental Metastasis · doi:10.1007/s10585-007-9095-5 · Cited by 109
Human osteosarcoma cells express functional receptor activator of nuclear factor‐kappa B
Mori, K., Le Goff, B., Berreur, M., Riet, A., Moreau, A., Blanchard, F., Chevalier, C., Guisle‐Marsollier, I., Léger, J., Guicheux, J., et al. (2007) · The Journal of Pathology · doi:10.1002/path.2140 · Cited by 100
“More recently, Jones et al [5] demonstrated RANK expres- sion on cancer cell lines as well as in patients with breast cancer.”
BackgroundInfluentialPrkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice
Molyneux, S. D., Di Grappa, M. A., Beristain, A. G., McKee, T. D., Wai, D. H., Paderova, J., Kashyap, M., Hu, P., Maiuri, T., Narala, S. R., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42391 · Cited by 99
“Additionally, RANKL is known to be functionally important for metastasis to bone (36).”
Self-citationPlatelets govern pre-metastatic tumor communication to bone
Kerr, B. A., McCabe, N. P., Feng, W., & Byzova, T. V. (2012) · Oncogene · doi:10.1038/onc.2012.447 · Cited by 107
Molecular Mechanisms of Bone Metastasis and Associated Muscle Weakness
Waning, D. L., & Guise, T. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1590 · Cited by 106
“Receptor activator of nuclear factor k-B (RANK) mediates osteoclast induced bone resorption and supports tumor cell colonization (23).”
BackgroundDenosumab in patients with cancer—a surgical strike against the osteoclast
Brown, J. E., & Coleman, R. E. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.197 · Cited by 105
Neville-Webbe, H. L., & Coleman, R. E. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.041 · Cited by 105
Periodontal Disease and Breast Cancer: Prospective Cohort Study of Postmenopausal Women
Freudenheim, J. L., Genco, R. J., LaMonte, M. J., Millen, A. E., Hovey, K. M., Mai, X., Nwizu, N., Andrews, C. A., & Wactawski-Wende, J. (2016) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-15-0750 · Cited by 95
Arai, A., Mizoguchi, T., Harada, S., Kobayashi, Y., Nakamichi, Y., Yasuda, H., Penninger, J. M., Yamada, K., Udagawa, N., & Takahashi, N. (2012) · Journal of Cell Science · doi:10.1242/jcs.099986 · Cited by 104
Self-citationLeone, K., Poggiana, C., & Zamarchi, R. (2018) · Diagnostics · doi:10.3390/diagnostics8030059 · Cited by 103
“In a mouse model, tumor cells expressing RANK were shown to migrate to the bone, perhaps attracted by RANKL, which is abundantly expressed in this tissue [204].”
BackgroundMicrofluidic platform for studying osteocyte mechanoregulation of breast cancer bone metastasis
Mei, X., Middleton, K., Shim, D., Wan, Q., Xu, L., Ma, Y.-H. V., Devadas, D., Walji, N., Wang, L., Young, E. W. K., et al. (2019) · Integrative Biology · doi:10.1093/intbio/zyz008 · Cited by 87
Peptidomimetic inhibitors of APC–Asef interaction block colorectal cancer migration
Jiang, H., Deng, R., Yang, X., Shang, J., Lu, S., Zhao, Y., Song, K., Liu, X., Zhang, Q., Chen, Y., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2442 · Cited by 102
Haroun, R., Wood, J. N., & Sikandar, S. (2023) · Frontiers in Pain Research · doi:10.3389/fpain.2022.1030899 · Cited by 101
“is a chemotactic factor that promotes bone metastasis (110), and chemokine receptors such as CXCR4 (C-X chemokine receptor 4), which binds the survival chemokine stromal cell-derived factor 1 present on osteoblasts and bone lining cells, promote adhesion and metastasis within the bone microenvironment (111, 112).”
BackgroundOsteoimmunology at the nexus of arthritis, osteoporosis, cancer, and infection
Jones, D., Glimcher, L. H., & Aliprantis, A. O. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46262 · Cited by 91
Self-citationDevignes, C.-S., Aslan, Y., Brenot, A., Devillers, A., Schepers, K., Fabre, S., Chou, J., Casbon, A.-J., Werb, Z., & Provot, S. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718009115 · Cited by 100
“Osteoblasts act either indirectly by stimulating bone resorption through osteoclasts (2, 3), which releases growth factors embedded in the bone matrix, or more directly by secreting chemoattractant factors (1) or establishing cell–cell contacts through adherent junctions with breast cancer cells (4).”
BackgroundJørgensen, J. R., Fransson, A., Fjord-Larsen, L., Thompson, L. H., Houchins, J. P., Andrade, N., Torp, M., Kalkkinen, N., Andersson, E., Lindvall, O., et al. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2011.09.027 · Cited by 87
“The actin cytoskeleton plays a central role in cell migration and SDF1a is known to induce actin polymerisation in multiple systems as an essential part of the migratory process (Jones et al., 2006; Voermans et al., 2001).”
Li, B., Wang, P., Jiao, J., Wei, H., Xu, W., & Zhou, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.824117 · Cited by 98
Denosumab: A comprehensive review
Narayanan, P. (2013) · South Asian Journal of Cancer · doi:10.4103/2278-330x.119895 · Cited by 97
“RANK, RANKL, and its soluble decoy receptor OPG play an essential role in the regulation of this process.”
BackgroundMiR-335 Inhibits Small Cell Lung Cancer Bone Metastases via IGF-IR and RANKL Pathways
Gong, M., Ma, J., Guillemette, R., Zhou, M., Yang, Y., Yang, Y., Hock, J. M., & Yu, X. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0136 · Cited by 97
“Blocking RANKLmarkedly reduced tumor burden in bones (47).”
BackgroundEffects of RANKL-Targeted Therapy in Immunity and Cancer
Cheng, M. L., & Fong, L. H. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2013.00329 · Cited by 96
“These findings were independent of osteoclast-mediated effects (61).”
BackgroundMori, K., Le Goff, B., Charrier, C., Battaglia, S., Heymann, D., & Rédini, F. (2007) · Bone · doi:10.1016/j.bone.2006.11.006 · Cited by 95
“have more recently reported the expression of fun ctio al RANK on human breast cancer (MDA-MB231, Hs578T, MCF 7), human prostate cancer (LNCaP, DU145) and mouse melanoma (B16F10) cell lin es [30].”
BackgroundNonopioid Drugs in the Treatment of Cancer Pain
Vardy, J. L., & Agar, M. R. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.8356 · Cited by 95
Role of Nuclear Factor-ĸB in Breast and Colorectal Cancer
Zubair, A. S., & Frieri, M. (2012) · Current Allergy and Asthma Reports · doi:10.1007/s11882-012-0300-5 · Cited by 94
Shedding of RANKL by Tumor-Associated MT1-MMP Activates Src-Dependent Prostate Cancer Cell Migration
Sabbota, A. L., Kim, H.-R. C., Zhe, X., Fridman, R. A., Bonfil, R. D., & Cher, M. L. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4416 · Cited by 94
Cathepsin K inhibitors as treatment of bone metastasis
Gall, C. L., Bonnelye, E., & Clézardin, P. (2008) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0b013e32830baea9 · Cited by 94
Osteoclasts and the immune system
Nakashima, T., & Takayanagi, H. (2009) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-009-0089-z · Cited by 94
“In addition, previous studies have indicated that RANKL serves as both a chemotactic and survival factor for osteoclasts [29, 30].”
BackgroundSelf-citationThe Molecular Mechanism of Vitamin E as a Bone-Protecting Agent: A Review on Current Evidence
Wong, S. K., Mohamad, N.-V., Ibrahim, N. ‘., Chin, K., Shuid, A. N., & Ima-Nirwana, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061453 · Cited by 93
Soluble RANKL is physiologically dispensable but accelerates tumour metastasis to bone
Asano, T., Okamoto, K., Nakai, Y., Tsutsumi, M., Muro, R., Suematsu, A., Hashimoto, K., Okamura, T., Ehata, S., Nitta, T., et al. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0104-1 · Cited by 92
Mukherjee, A., Soyal, S. M., Li, J., Yan, Y., He, B., DeMayo, F. J., & Lydon, J. P. (2010) · The FASEB Journal · doi:10.1096/fj.10-157982 · Cited by 92
“osteoclast differentiation, dendritic cell survival, T-cell communication, and lymph node organogenesis, as well as tumor cell migration and metastasis (17, 19).”
BackgroundYamamoto, M., Gohda, J., Akiyama, T., & Inoue, J. (2021) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.97.009 · Cited by 91
Homing of Cancer Cells to the Bone
Mishra, A., Shiozawa, Y., Pienta, K. J., & Taichman, R. S. (2011) · Cancer Microenvironment · doi:10.1007/s12307-011-0083-6 · Cited by 91
“This further supports the role if RANKL in bone specific metastasis [134].”
BackgroundEffect of peripheral endothelin‐1 concentration on carcinoma‐induced pain in mice
Pickering, V., Gupta, R. J., Quang, P. N., Jordan, R. C., & Schmidt, B. L. (2007) · European Journal of Pain · doi:10.1016/j.ejpain.2007.06.001 · Cited by 90
“Melanoma can be painful in humans both at the primary site and at metastatic sites (Pandey et al., 1998; Jones et al., 2006; Noorda et al., 2007).”
BackgroundNovel therapeutic agents for osteosarcoma
O’Day, K., & Gorlick, R. G. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.7 · Cited by 89
Lee, S.-J., Nam, K. I., Jin, H., Cho, Y., Lee, S.-E., Kim, T., Lee, S., Kee, S., Lee, K., Kim, N., et al. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3483 · Cited by 88
“Previous studies have demonstrated that RANKL serves as both a chemotactic and survival factor for osteoclasts [14,15], and its expression can be up-regulated by proresorptive cytokines, such as interleukin (IL)-1, IL-6 and tumor necrosis factor (TNF)-a [16-18].”
BackgroundTumoral RANKL activates astrocytes that promote glioma cell invasion through cytokine signaling
Kim, J.-K., Jin, X. J., Sohn, Y.-W., Jin, X., Jeon, H.-Y., Kim, E. J., Ham, S. W., Jeon, H.-M., Chang, S. Y., Oh, S.-Y., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.07.034 · Cited by 87
β2-Microglobulin-mediated Signaling as a Target for Cancer Therapy
Nomura, T., Huang, W., Zhau, H. E., Josson, S., Mimata, H., & Chung, L. W. K. (2014) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/18715206113139990092 · Cited by 87
“RANKL (associated with cancer cells or osteoblasts) and its TNF-family receptor RANK (associated with osteoclasts) are essential regulators of bone remodeling and bone metastasis in cancer [80].”
BackgroundKey roles of the OPG–RANK–RANKL system in bone oncology
Baud’huin, M., Duplomb, L., Velasco, C. R., Fortun, Y., Heymann, D., & Padrines, M. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.2.221 · Cited by 87
Meng, Y., Zhou, W., Jin, L., Liu, L.-B., Chang, K., Mei, J., Li, H., Wang, J., Li, D., & Li, M. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.505 · Cited by 87
“thereby fundamental aspects of bone physiology, bone remodeling,(13,14) lymph node formation,(15) establishment of thymic microenvironment,(16) mammary gland development during pregnancy(17,18) and bone metastasis of cancer.(19)”
BackgroundLi, X., Wang, Y., Chen, Y., Zhou, P., Wei, K., Wang, H., Wang, J., Fang, H., & Zhang, S. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120253 · Cited by 86
Huang, D., Zhao, C., Li, R., Chen, B., Zhang, Y., Sun, Z., Wei, J., Zhou, H., Gu, Q., & Xu, J. (2022) · Nature Communications · doi:10.1038/s41467-022-33006-4 · Cited by 85
Targeting the RANKL/RANK/OPG Axis for Cancer Therapy
Ming, J., Cronin, S. J. F., & Penninger, J. M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01283 · Cited by 84
“In a murine model of melanoma metastasis, it was found that for malignant tumors with RANK expression, RANKL produced by osteoblasts and bone marrow stromal cells could act as a chemical attractant and promote the migration and metastasis of malignant tumors to these sites (132).”
BackgroundSelf-citationClinical significance of CYLD downregulation in breast cancer
Hayashi, M., Jono, H., Shinriki, S., Nakamura, T., Guo, J., Sueta, A., Tomiguchi, M., Fujiwara, S., Yamamoto‐Ibusuki, M., Murakami, K.-I., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2824-3 · Cited by 83
“malignancies including breast cancer [41, 42].”
Rebalancing the Oral Microbiota as an Efficient Tool in Endocrine, Metabolic and Immune Disorders
Isacco, C. G., Ballini, A., Vito, D. D., Nguyen, K. C. D., Cantore, S., Bottalico, L., Quagliuolo, L., Boccellino, M., Domenico, M. D., Santacroce, L., et al. (2020) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530320666200729142504 · Cited by 82
The Breast Tumor Microenvironment: A Key Player in Metastatic Spread
Terceiro, L. E. L., Edechi, C. A., Ikeogu, N. M., Nickel, B. E., Hombach‐Klonisch, S., Sharif, T., Leygue, E., & Myal, Y. (2021) · Cancers · doi:10.3390/cancers13194798 · Cited by 81
Bone Metastases: Molecular Mechanisms and Novel Therapeutic Interventions
Papachristou, D. J., Basdra, E. K., & Papavassiliou, A. G. (2010) · Medicinal Research Reviews · doi:10.1002/med.20224 · Cited by 81
“These data suggest an addition role of the RANK–RANKL system in the pathogenesis of skeletal metastasis that extends beyond its function on osteoclasts.(32)”
BackgroundMori, K., Berreur, M., Blanchard, F., Chevalier, C., Guisle, I., Masson, M., Rédiní, F., & Heymann, D. (2007) · Oncology Reports · doi:10.3892/or.18.6.1365 · Cited by 81
“Furthermore, recent finding clearly suggested a pivotal role of RANK in bone-associated tumors by presenting RANKL-triggered RANK-positive cell migration (8,9).”
BackgroundInfluentialDougall, W. C., Holen, I., & González‐Suárez, E. (2014) · BoneKEy Reports · doi:10.1038/bonekey.2014.14 · Cited by 81
“Working from the observation that RANKL directly stimulates B16F10 melanoma cell migration in vitro (see below), Jones et al.(41) tested whether a RANKL inhibitor would block B16F10 metastasis in vivo in an experimental bone metastasis model.”
BackgroundBlair, J. M., Zheng, Y., & Dunstan, C. R. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2006.11.008 · Cited by 81
Molecular and Cellular Mechanisms of Photocarcinogenesis†
Beissert, S., & Loser, K. (2007) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.2007.00231.x · Cited by 80
Casimiro, S., Mohammad, K. S., Pires, R., Tato-Costa, J., Alho, I., Teixeira, R. L., Carvalho, A., Ribeiro, S., Lipton, A., Guise, T. A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063153 · Cited by 80
Aicher, A., Kollet, O., Heeschen, C., Liebner, S., Urbich, C., Ihling, C., Orlandi, A., Lapidot, T., Zeiher, A. M., & Dimmeler, S. (2008) · Circulation Research · doi:10.1161/circresaha.107.172718 · Cited by 73
Sisay, M., Mengistu, G., & Edessa, D. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s135867 · Cited by 80
RANKL and RANK in sex hormone-induced breast cancer and breast cancer metastasis
Schramek, D., Sigl, V., & Penninger, J. M. (2011) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2011.02.007 · Cited by 79
Self-citationThe dynamic interplay between osteoclasts and the immune system
Nakashima, T., & Takayanagi, H. (2008) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2008.04.004 · Cited by 78
Self-citationClinical development of anti-RANKL therapies for treatment and prevention of bone metastasis
Lipton, A., & Goessl, C. D. (2010) · Bone · doi:10.1016/j.bone.2010.10.161 · Cited by 78
Huang, S. C. M., Tsao, S. W., & Tsang, C. M. (2018) · Cancers · doi:10.3390/cancers10040106 · Cited by 78
“A recent study has shown that NPC metastases express high levels of RANK, despite unavailable results in primary NPC tumors [134].”
BackgroundInfluentialFrom latency to overt bone metastasis in breast cancer: potential for treatment and prevention
Salvador, F., Lope, A. L., & Gomis, R. R. (2019) · The Journal of Pathology · doi:10.1002/path.5292 · Cited by 76
“Moreover, RANK-expressing cells can be attracted to osteolytic areas in which high levels of RANKL are produced, favoring cancer cell migration and bone metastasis [50] (Figure 1).”
BackgroundNatural and Synthetic Estrogens in Chronic Inflammation and Breast Cancer
Maharjan, C. K., Mo, J., Wang, L. A., Kim, M., Wang, S., Borcherding, N. C., Vikas, P., & Zhang, W. (2021) · Cancers · doi:10.3390/cancers14010206 · Cited by 76
Bone metastases in non-small cell lung cancer: a narrative review
Knapp, B. J., Devarakonda, S. H. K., & Govindan, R. (2022) · Journal of Thoracic Disease · doi:10.21037/jtd-21-1502 · Cited by 75
“Denosumab inhibition of RANK-L may have a direct anti-neoplastic effect via apoptosis or anti-migration of tumor cells (88,89).”
CXCR4 Expression in Early Breast Cancer and Risk of Distant Recurrence
André, F., Xia, W., Conforti, R., Wei, Y., Boulet, T., Tomasic, G., Spielmann, M., Zoubir, M., Berrada, N., Arriagada, R., et al. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0161 · Cited by 75
Emerging roles of the tumor-associated stroma in promoting tumor metastasis
Horimoto, Y., Polanska, U. M., Takahashi, Y., & Orimo, A. (2012) · Cell Adhesion & Migration · doi:10.4161/cam.20631 · Cited by 74
“2B).(93) RANKL is produced by osteoblasts and other stromal cells and this cytokine binds to RANK receptors expressed mainly on osteoclast progenitors that stimulates these cells to differentiate into active osteoclasts, leading to excessive bone loss.”
BackgroundMethodResultInfluentialDisrupting the Stem Cell Niche: Good Seeds in Bad Soil
Perry, J. M., & Li, L. (2007) · Cell · doi:10.1016/j.cell.2007.05.053 · Cited by 74
“Indeed, bone marrow is a preferred site for metastasis of certain cancers (Jones et al., 2006).”
Invasion and metastasis of renal cell carcinoma
Mikami, S., Oya, M., Mizuno, R., Kosaka, T., Katsube, K., & Okada, Y. (2013) · Medical Molecular Morphology · doi:10.1007/s00795-013-0064-6 · Cited by 73
Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells
Rachner, T. D., Singh, S. K., Schoppet, M., Benad, P., Bornhäuser, M., Ellenrieder, V., Ebert, R., Jakob, F. J., & Hofbauer, L. C. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.06.003 · Cited by 73
“Enhanced OPG expression may increase ligation of RANKL and thereby reduce the capability of tumor cells to metastasize to the skeleton [35], but could also result in a better protection from TRAIL-induced apoptosis [14].”
BackgroundMultimodal Treatment of Bone Metastasis—A Surgical Perspective
Soeharno, H., Povegliano, L., & Choong, P. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00518 · Cited by 73
“Recent studies have also shown that blocking RANKL action on tumor cells had an inhibitory effect on tumor cells in in vitro and animal models, although the exact mechanism is not fully understood (87, 88).”
BackgroundThe systemic hallmarks of cancer
Paul, D. (2020) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2020.63 · Cited by 73
“For example, sympathetic innervation of bone marrow can stimulate the production of myeloid lineage immune cells which may infiltrate the tumoral microenvironment and promote metastasis([209-211]).”
BackgroundFuruya, Y., Mori, K., Ninomiya, T., Tomimori, Y., Tanaka, S., Takahashi, N., Udagawa, N., Uchida, K., & Yasuda, H. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.246280 · Cited by 71
Osteoclastogenesis and arthritis
Maruotti, N., Grano, M., Colucci, S. C., Donofrıo, F., & Cantatore, F. P. (2010) · Clinical and Experimental Medicine · doi:10.1007/s10238-010-0117-2 · Cited by 72
“Moreover, RANKL plays a role as chemotactic and survival factor for osteoclasts [11, 12].”
BackgroundRANK Is Expressed in Metastatic Melanoma and Highly Upregulated on Melanoma-Initiating Cells
Kupas, V., Weishaupt, C., Siepmann, D., Kaserer, M.-L., Eickelmann, M., Metze, D., Luger, T. A., Beissert, S., & Loser, K. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.377 · Cited by 71
Fili, S., Karalaki, M., & Schaller, B. J. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.01.011 · Cited by 71
Emerging Therapeutic Targets in Breast Cancer Bone Metastasis
Rose, A. A. N., & Siegel, P. M. (2009) · Future Oncology · doi:10.2217/fon.09.138 · Cited by 71
“Additionally, breast cancer cells express RANK, the receptor for RANKL, and RANKL stimu lation is capable of inducing the migration of MDAMB231, Hs578T and MCF7 breast cancer cells [88].”
BackgroundBrodowicz, T., O'Byrne, K. J., & Manegold, C. (2012) · Annals of Oncology · doi:10.1093/annonc/mds009 · Cited by 71
“RANKL may also trigger tumour cell proliferation [67] and promote migration of RANK-expressing tumour cells to bone [68].”
BackgroundMei, S., Alchahin, A. M., Τσέα, Ι., Kfoury, Y. S., Hirz, T., Jeffries, N. E., Zhao, T., Xu, Y., Zhang, H., Sarkar, H., et al. (2024) · Genome Medicine · doi:10.1186/s13073-023-01272-6 · Cited by 72
“This observation suggests a specific activation of the RANKL-RANK axis within the tumor [66].”
BackgroundDevelopment and Function of Murine B Cells Lacking RANK
Perlot, T., & Penninger, J. M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102063 · Cited by 70
Self-citationSekita, A., Matsugaki, A., Ishimoto, T., & Nakano, T. (2016) · Journal of Structural Biology · doi:10.1016/j.jsb.2016.12.003 · Cited by 70
Metadata
- Authors
- Jones, D. H., Nakashima, T., Sanchez, O. H., Kozieradzki, I., Komarova, S. V., Sarosi, I., Morony, S., Rubin, E., Sarao, R., Hojilla, C. V., Komnenovic, V., Kong, Y.-Y., Schreiber, M., Dixon, S. J., Sims, S. M., Khokha, R., Wada, T., & Penninger, J. M.
- Affiliations
- Institute of Molecular Biotechnology (AT)
- University Health Network (CA)
- McGill University (CA)
- Amgen (United States) (US)
- University of Toronto (CA)
- Pohang University of Science and Technology (KR)
- Medical University of Vienna (AT)
- Western University (CA)
- Corresponding author
- Penninger, Josef M.
- ORCID
- Venue
- Nature
- Published
- 2006-03
- Volume
- 440
- Issue
- 7084
- Pages
- 692-696
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2051255001
- Cited by
- 796
- References
- 22
- Citations by year
- 2026: 10 · 2025: 21 · 2024: 24 · 2023: 32 · 2022: 33 · 2021: 43 · 2020: 43 · 2019: 39 · 2018: 28 · 2017: 43 · 2016: 36 · 2015: 42 · 2014: 45 · 2013: 47 · 2012: 68
- FWCI
- 18.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Scholarship@Western (Western University) (submittedVersion)
- Open Access System for Information Sharing (Pohang University of Science and Technology) (submittedVersion)
- Funders
- European Commission
- Oesterreichische Nationalbank
- Canadian Institutes of Health Research
- National Cancer Institute
- Institute of Musculoskeletal Health and Arthritis
- Canadian Arthritis Network
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- RANKL, RANK, bone metastasis, tumor cell migration, osteoprotegerin, melanoma, breast cancer, tumor microenvironment, NF-κB signaling
- MeSH terms
- Animals, Bone Neoplasms, Breast Neoplasms, Carrier Proteins, Cell Differentiation, Cell Movement, Epithelial Cells, Female, Humans, Melanoma, Membrane Glycoproteins, Neoplasm Metastasis, Organ Specificity, Paralysis, Signal Transduction, Cell Death, Cell Line, Tumor, Cell Proliferation, Mice, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.